Groowe Groowe / Newsroom / CERO
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CERO News

CERo Therapeutics Holdings, Inc. Common Stock

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

globenewswire.com
CERO

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

globenewswire.com
CERO

CERo Therapeutics Provides Shareholder Update

globenewswire.com
CERO

CERo Therapeutics Provides Shareholder Update

globenewswire.com
CERO

Form 8-K

sec.gov
CERO CEROW

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

globenewswire.com
CERO

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

globenewswire.com
CERO

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

globenewswire.com
CERO

City of Quincy Partners with Cero Global to Launch Pilot Reducing Emissions and Fuel Costs

prnewswire.com
CERO

CERo Therapeutics Announces Trading on OTCQB Market

globenewswire.com
CERO